Researchers at the University of North Carolina have created a novel immunotherapy that targets acute myeloid leukemia (AML) without harming healthy blood cells, addressing a critical challenge in treating this aggressive blood cancer. The findings, published in the journal Blood, could lead to safer and more effective therapies for patients with limited options.
Led by immunologist Gianpietro Dotti and hematologist Paul Armistead, the research teams engineered immune cells to recognize and eliminate leukemia cells while leaving normal blood tissue intact. This precision approach overcomes a major hurdle in AML treatment, where traditional therapies often fail to distinguish between cancerous and healthy cells, leading to severe side effects or incomplete eradication of the disease.
"Our goal was to design a therapy that could selectively target leukemic cells without destroying the healthy blood system," said Dotti. The team's work represents a significant step forward in immunotherapy, which harnesses the body's immune system to fight cancer. While current immunotherapies have shown success in some blood cancers, they have been less effective against AML due to the similarity between cancerous and normal cells.
The engineered cells, known as chimeric antigen receptor (CAR) T cells, were modified to recognize a protein found on AML cells but not on healthy blood stem cells. In laboratory tests, the cells successfully killed leukemia cells while preserving healthy bone marrow function. The researchers believe this approach could be developed into a treatment that reduces toxicity and improves outcomes for AML patients.
Further research is needed to confirm the safety and efficacy of this approach in clinical trials. However, the study opens the door to more advanced and potentially side-effect-free cancer therapies. Companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) are also pursuing innovative cancer treatments, focusing on oncolytic virus therapies that target tumors while sparing healthy tissue.
The University of North Carolina team's work highlights the potential of precision immunotherapy in addressing some of the most challenging cancers. By refining CAR T cells to avoid off-target effects, researchers are moving closer to therapies that can effectively treat AML without compromising the patient's overall health.
